Health IT Analytics November 8, 2022
Mark Melchionna

Artificial intelligence supported a clinical trial that found that low-dose ketamine could be a therapeutic target for a rare genetic disease.

Artificial intelligence (AI) supported a clinical trial focused on assessing treatment methods for a rare genetic disease known as activity-dependent neuroprotective protein (ADNP) syndrome.

ADNP syndrome is a rare condition due to a mutation of the ADNP gene. The disease affects the brain and various body functions, including hearing and vision, according to the National Institutes of Health.

Researchers from the Hugh Kaul Precision Medicine Institute at the University of Alabama at Birmingham used an AI tool known as mediKanren that flagged useful clinical evidence, helping them identify low-dose ketamine as a potential therapeutic target for ADNP syndrome.

...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Clinical Trials, Provider, Technology, Trends
Amazon invests another $2.75B in Anthropic — reportedly ‘largest’ in company history
Policy at global conference focuses on three central issues
How Remote Patient Monitoring and AI Personalize Care
How Nebraska Medicine used AI to reduce first-year nurse turnover by nearly 50%
Social Isolation Linked to Being Older Than Biological Age, Greater Mortality

Share This Article